RU94045280A - Средство для ингибирования патологических состояний молочных желез - Google Patents

Средство для ингибирования патологических состояний молочных желез

Info

Publication number
RU94045280A
RU94045280A RU94045280/14A RU94045280A RU94045280A RU 94045280 A RU94045280 A RU 94045280A RU 94045280/14 A RU94045280/14 A RU 94045280/14A RU 94045280 A RU94045280 A RU 94045280A RU 94045280 A RU94045280 A RU 94045280A
Authority
RU
Russia
Prior art keywords
mamma
inhibition
agent
pathological states
gland pathological
Prior art date
Application number
RU94045280/14A
Other languages
English (en)
Other versions
RU2126251C1 (ru
Inventor
Джозеф Сейлс Джеймс
Us]
Джозеф Каллинан Джордж
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94045280A publication Critical patent/RU94045280A/ru
Application granted granted Critical
Publication of RU2126251C1 publication Critical patent/RU2126251C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Предложен способ подавления патологических состояний молочных желез, заключающийся в том, что человеку, нуждающемуся в устранении указанных состояний, вводят эффективное количество соединения формулы, приведенной в описании, либо его фармацевтически приемлемой соли или сольвата.

Claims (1)

  1. Предложен способ подавления патологических состояний молочных желез, заключающийся в том, что человеку, нуждающемуся в устранении указанных состояний, вводят эффективное количество соединения формулы, приведенной в описании, либо его фармацевтически приемлемой соли или сольвата.
RU94045280A 1993-12-21 1994-12-16 Средство для ингибирования патологических состояний молочных желез RU2126251C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,955 US5593987A (en) 1993-12-21 1993-12-21 Methods of inhibiting breast disorders
US08/171,955 1993-12-21

Publications (2)

Publication Number Publication Date
RU94045280A true RU94045280A (ru) 1996-10-10
RU2126251C1 RU2126251C1 (ru) 1999-02-20

Family

ID=22625779

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045280A RU2126251C1 (ru) 1993-12-21 1994-12-16 Средство для ингибирования патологических состояний молочных желез

Country Status (15)

Country Link
US (1) US5593987A (ru)
EP (1) EP0659419A1 (ru)
JP (1) JPH07196501A (ru)
KR (1) KR950016729A (ru)
CN (1) CN1108100A (ru)
AU (1) AU701701B2 (ru)
CA (1) CA2138501A1 (ru)
CZ (1) CZ321294A3 (ru)
HU (1) HUT71480A (ru)
IL (1) IL112039A (ru)
NO (1) NO944933L (ru)
NZ (1) NZ270170A (ru)
PH (1) PH31326A (ru)
RU (1) RU2126251C1 (ru)
ZA (1) ZA9410088B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
WO2002003986A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
ITMI20011495A1 (it) * 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
ITMI20041279A1 (it) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001242A (en) * 1974-08-02 1977-01-04 Eli Lilly And Company D-6-methyl-8-formyl-10α-alkoxy-8-ergolene
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5227375A (en) * 1990-02-08 1993-07-13 Endorecherche, Inc. Aromatase inhibitors
FR2677027B1 (fr) * 1991-05-27 1993-09-10 Roussel Uclaf Nouveaux produits sterouides substitues en position 6, et comportant, en position 10, un radical thioethyle, leur procede de preparation leurs intermediaires, leur application comme medicaments.
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
AU8156094A (en) 1995-06-29
AU701701B2 (en) 1999-02-04
CA2138501A1 (en) 1995-06-22
JPH07196501A (ja) 1995-08-01
KR950016729A (ko) 1995-07-20
ZA9410088B (en) 1996-06-19
NZ270170A (en) 1997-07-27
EP0659419A1 (en) 1995-06-28
HU9403666D0 (en) 1995-02-28
HUT71480A (en) 1995-11-28
RU2126251C1 (ru) 1999-02-20
IL112039A0 (en) 1995-03-15
CN1108100A (zh) 1995-09-13
IL112039A (en) 1999-03-12
CZ321294A3 (en) 1995-08-16
PH31326A (en) 1998-07-06
NO944933D0 (no) 1994-12-19
US5593987A (en) 1997-01-14
NO944933L (no) 1995-06-22

Similar Documents

Publication Publication Date Title
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94036772A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94045280A (ru) Средство для ингибирования патологических состояний молочных желез
CA2104873A1 (en) Compositions and Methods of Treatment of Sympathetically Maintained Pain
GB0225475D0 (en) Therapeutic agents
NZ333800A (en) Apoptosis inducing adamantyl derivatives and pharmaceutical uses
RU94045155A (ru) Способы ингибирования болезни альцгеймера
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
NZ335013A (en) Compositions comprising cytosine derivatives for the treatment of cancer
RU94045278A (ru) Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом
MX9803809A (es) Inhibidores de hidroxamato de bifenilo de metaloproteinasas de matriz.
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
PT1664016E (pt) Agentes terapêuticos úteis para tratamento da dor
RU94036771A (ru) Ингибиторы ангиогенеза и ангиогенных заболеваний
RU94037233A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
RU94045277A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования расстройств цнс у женщин в постменопаузе
RU94045156A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования преждевременного полового созревания